Prescriber Compliance With Liver Monitoring Guidelines for Pazopanib in the Postapproval Setting: Results From a Distributed Research Network

OBJECTIVES: Pazopanib received US Food and Drug Administration approval in 2009 for advanced renal cell carcinoma. During clinical development, liver chemistry abnormalities and adverse hepatic events were observed, leading to a boxed warning for hepatotoxicity and detailed label prescriber guidelin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Patient Saf
Autors principals: Shantakumar, Sumitra, Nordstrom, Beth L., Hall, Susan A., Djousse, Luc, van Herk-Sukel, Myrthe P.P., Fraeman, Kathy H., Gagnon, David R., Chagin, Karen, Nelson, Jeanenne J.
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2019
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6407814/
https://ncbi.nlm.nih.gov/pubmed/28430700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PTS.0000000000000332
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars